Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs

in the San Diego-Tijuana border region

- 3 Steffanie A. Strathdee^{1*}, Daniela Abramovitz¹, Alicia Harvey-Vera^{1, 2, 4}, Carlos Vera¹, Gudelia Rangel^{3,4},
- 4 Irina Artamonova¹, Antoine Chaillon¹, Caroline Ignacio⁵, Alheli Calderon^{1,6}, Natasha K. Martin¹, Thomas L.
- 5 Patterson⁷
- 6 **Affiliations:** ¹Division of Infectious Diseases and Global Public Health, Department of Medicine,
- 7 University of California San Diego, La Jolla, CA, United States of America; ²Universidad Xochicalco,
- 8 Facultad de Medicina, Campus Tijuana, Mexico; ³Departmento de Estudios de Población, El Colegio de
- 9 la Frontera Norte, Tijuana, Mexico; ⁴United States-Mexico Border Health Commission, Tijuana, Mexico;
- ⁵CFAR Translational Virology Core, Department of Medicine, University of California San Diego, La Jolla,
- 11 CA, United States of America; ⁶School of Public Health, San Diego State University, San Diego,
- 12 California, United States of America; ⁷Department of Psychiatry, University of California, San Diego, La
- 13 Jolla, CA, United States of America
- 14 *Corresponding Author:

16

1

2

15 E-mail: sstrathdee@health.ucsd.edu

Abstract

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

Background: People who inject drugs may be at elevated SARS-CoV-2 risk due to their living conditions and/or exposures when seeking or using drugs. No study to date has reported upon risk factors for SARS-CoV-2 infection among people who inject drugs or sex workers. Methods and Findings: Between October, 2020 and June, 2021, participants aged ≥18 years from San Diego, California, USA and Tijuana, Baja California, Mexico who injected drugs within the last month underwent interviews and testing for SARS-CoV-2 RNA and antibodies. Binomial regressions identified correlates of SARS-CoV-2 seropositivity. Of 386 participants, SARS-CoV-2 seroprevalence was 36.3% (95% CI: 31.5%-41.1%); 92.1% had detectable IgM antibodies. Only 37.5% had previously been tested. Seroprevalence did not differ by country of residence. None tested RNA-positive. Most (89.5%) reported engaging in ≥1 protective behavior [e.g., facemasks (73.5%), social distancing (46.5%), or increasing handwashing/sanitizers (22.8%)]. In a multivariate model controlling for sex, older age, and Hispanic/Latinx/Mexican ethnicity were independently associated with SARS-CoV-2 seropositivity, as was engaging in sex work (AdjRR: 1.63; 95% CI: 1.18-2.27) and having been incarcerated in the past six months (AdjRR: 1.49; 95% CI: 0.97-2.27). Presence of comorbidities and substance using behaviors were not associated with SARS-CoV-2 seropositivity. Conclusions: This is the first study to show that sex work and incarceration were independently associated with SARS-CoV-2 infection. Despite engaging in protective measures, over one-third had evidence of infection, reinforcing the need for a coordinated binational response. Risk mitigation and vaccination is especially needed among older and Hispanic people who inject drugs and those with less agency to protect themselves, such as those who are sex workers or incarcerated.

Introduction

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

63

The disproportionate burden of COVID-19 on under-represented minorities is well documented [1–3]. However, data are lacking on people with substance use disorders who may be vulnerable to acquiring and transmitting SARS-CoV-2 due to their living conditions (e.g., homelessness, incarceration) and drugrelated behaviors (e.g. smoking, vaping, sharing drug paraphernalia, sex work) [4,5]. In a nation-wide study, those with substance use disorders, especially African Americans and opioid users, were at increased risk of COVID-19 [6]. However, this study could not determine whether these factors were independently associated with COVID-19 diagnosis since risk factor data were not available, and the sample was restricted to patients accessing health care. In a telephone survey of active and former drug injectors in Baltimore, Maryland, compared to former substance users, those who were actively using substances were less likely to report social distancing [5]. There is also evidence that the COVID-19 pandemic has interrupted drug supplies as well as harm reduction and addiction treatment services [7]. Most epidemiologic research on COVID-19 has been conducted on inpatient samples and has focused on upper-income countries. We studied prevalence and correlates of SARS-CoV-2 infection in a binational community-based study of people who inject drugs residing in San Diego, California and Tijuana, Baja California, Mexico. We hypothesized a priori that residents of San Diego who had recently crossed the border to inject drugs in Tijuana and those who were homeless, traded sex or injected drugs more often would be more likely to test SARS-CoV-2 seropositive.

Materials and methods

San Diego County, California is home to approximately 1.42 million people. Its counterpart in Baja
California, Mexico is Tijuana, a city of ~1.5 million people, located twenty minutes from San Diego and
located on a major drug trafficking route. In an attempt to limit SARS-CoV-2 transmission, the U.S.Mexico border was closed to essential travel on March 21, 2020 for the eight months duration of the

Study Setting: As the eighth largest city in the U.S. and the largest situated on the Mexico-US border,

study.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

Participants and Eligibility. Between October 28, 2020 and June 16, 2021, street outreach was used to recruit participants aged ≥18 or older who injected drugs within the last month and reported living in San Diego County or Tijuana. We sought to enroll participants residing in San Diego who reported having crossed the border to inject drugs in Tijuana within the last two years as well as those from either city who reported not having used illicit drugs on the other side of the border. Survey Measures: After providing informed consent, participants underwent interviewer-administered surveys at baseline and approximately one week later to minimize participant burden. Computer assisted personal interviewing was used to minimize socially desirable responding. Survey items included sociodemographics, potential COVID-19 exposures (e.g., injection and non-injection drug use, sharing injection equipment, incarceration, sex work), vulnerabilities (e.g., homelessness, cross-border, mobility, food insecurity [8], impact of COVID-19 on income and housing), and protective behaviors (e.g., social distancing, use of face masks and handwashing/sanitizers). Participants were compensated \$20 USD. Protocols were approved by institutional review boards at the University of California San Diego and Xochicalco University. SARS-CoV-2 Antibody Detection. Serology was conducted by Genalyte® (San Diego, CA), using their Maverick™ Multi-Antigen Serology Panel [9] that detects IgG and IgM antibodies to five SARS-CoV-2 antigens (Nucleocapsid, Spike S1-S2, Spike S1, Spike S1-RBD, Spike S2) within a multiplex format based on photonic ring resonance. A machine learning algorithm was used to call results using the Random Forest Ensemble method with 3000 decision trees [10]. SARS-CoV-2 RNA Detection: Participants self-collected anterior nasal swabs which were placed in 3mL of viral transport media and stored for up to one week at 80 degrees Celsius before being shipped on ice for testing at the University of California San Diego (UCSD)'s Center for AIDS Research. RT-PCR was conducted using a pooling approach based on the Fluxergy system® (Irvine, CA) to detect SARS-CoV-2 RNA. HIV and HCV Serology. Rapid HIV and HCV tests were conducted using the Miriad® HIV/HCV Antibody InTec Rapid Anti-HCV Test (Avantor, Radnor, PA). Reactive and indeterminate tests underwent a second rapid test with Oraquick® HIV or Oraquick® HCV, respectively (Orasure, Bethlehem, PA).

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

Statistical Analysis: SARS-CoV-2 prevalence was calculated with 95% confidence intervals (CIs) based on the Binomial distribution. Those testing indeterminate were excluded. The Cochran-Armitage test was used to assess trends in SARS-CoV-2 seroprevalence. Characteristics of participants testing SARS-CoV-2 seropositive versus seronegative were compared using Wilcoxon Rank Sum for continuous variables and Chi-square or Fisher's Exact tests for categorical variables. Univariate and multivariable binomial regressions with robust standard error estimation via generalized estimating equations were performed to identify factors associated with SARS-CoV-2 seropositivity. Variables attaining <10% significance were considered for inclusion in multivariable models. All potential interactions between variables in the final model were assessed. Multi-collinearity was assessed using diagnostics such as largest condition index and variance inflation factors. Although site-specific models were examined, results were presented for the overall sample since associations were generally similar. Role of funding source: The funders had no involvement in the study design, collection, analysis, interpretation or writing of this rpreport, nor the decision to submit the paper for publication. Results Of 405 participants tested, none had detectable SARS-CoV-2 RNA. Considering serologic evidence of SARS-CoV-2 infection, 19 (4.7%) tested indeterminate and were excluded. Detectable SARS-CoV-2 IgG and/or IgM antibodies were observed in 36.3% [95% confidence interval (95% CI): 31.5%-41.1%], of whom the majority had IgM (92.1%). Of the 140 testing SARS-CoV-2 seropositive, only 37.5% had previously been tested, and 26.8% reported ≥1 current symptom consistent with COVID-19. There was no significant trend in seroprevalence over time (p=0.80). Of the 386 subjects included in the analysis, 63.5% lived in San Diego County. Most were male (74.1%) and Hispanic/Latinx/Mexican (71.5%). Median age was 43 (inter-quartile range [IQR: 35-51]. Over half reported that COVID-19 had adversely affected their housing or income. During the last six months, 39.1% were homeless, 8.3% were incarcerated and 12.4% traded sex (Table 1). Of the San Diego residents, 50.8% reported having crossed the border to inject drugs in Tijuana within the last six months.

Older age and identifying as Hispanic, Latinx, or Mexican were significantly associated with SARS-CoV-2 seropositivity (Table 1). Considering potential community exposures in the past six months (Table 2), those engaging in sex work were significantly more likely to test seropositive compared to those who did not (17.9% vs. 9.3%, p=0.01, [Relative Risk (RR): 1.53; 95% CI: 1.12-2.09]. Being incarcerated was associated with marginally higher SARS-CoV-2 seropositivity (RR: 1.43; 95% CI: 0.99-2.09). We did not observe injection drug use, smoking, vaping specific drugs or any other substance use behaviors to be associated with seroprevalence, nor were any co-morbidities (i.e., HIV, HCV, Type 2 diabetes, hypertension).

Table 1. Characteristics Associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico (N=386)

	SARS-CoV-2	SARS-CoV-2		
Basellas Okassataslatia	Seropositive	Seronegative	Total	Danis
Baseline Characteristics	N=140	N=246	N=386	P-value
Sociodemographics				
Male	104(74.3%)	182(74.0%)	286(74.1%)	.95
Median Age (IQR)	45.0(37.0,53.0)	42.0(34.0,50.0)	43.0(35.0,51.0)	.042
Hispanic/Latinx/Mexican	111(79.3%)	165(67.1%)	276(71.5%)	.01
Speaks English	98(70.0%)	185(75.2%)	283(73.3%)	.27
Born in the US	61(43.6%)	129(52.4%)	190(49.2%)	.09
Primary residence in San Diego	88(62.9%)	157(63.8%)	245(63.5%)	.85
Highest year of school completed (IQR)	11.0(8.0,12.0)	11.0(7.0,12.0)	11.0(7.0,12.0)	.99
Married or common law	25(17.9%)	49(19.9%)	74(19.2%)	.62
Average monthly income <500 USD	75(53.6%)	130(52.8%)	205(53.1%)	.89
Median years lived in Study Location (IQR)	30.0(10.0,45.0)	26.5(10.0,40.0)	28.0(10.0,41.0)	.20
Potential Exposures				
Homeless*	50(35.7%)	101(41.1%)	151(39.1%)	.30
Incarcerated*	16(11.5%)	16(6.5%)	32(8.3%)	.12
Median # of people in household (IQR)*	2.0(1.0, 4.0)	2.0(1.0, 5.0)	2.0(1.0, 4.0)	.71
Low/very low food security	88(78.6%)	171(80.3%)	259(79.7%)	.72
Engaged in sex work*	25(17.9%)	23(9.3%)	48(12.4%)	.01
Client of sex worker*	8(5.7%)	10(4.1%)	18(4.7%)	.46
Exposed to someone with COVID-19	6(5.4%)	12(5.6%)	18(5.5%)	1.0
Impact of Pandemic				
Housing situation worse	91(65.0%)	140(56.9%)	231(59.8%)	.12
Income worse	98(70.5%)	149(62.3%)	247(65.3%)	.11
Substance Use				
Smokes cigarettes	118(84.3%)	222(90.2%)	340(88.1%)	.08

Table 1 (continued). Characteristics Associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico (N=386)

	SARS-CoV-2	SARS-CoV-2		
Basellas Observatoristics	Seropositive	Seronegative	Total	Danish
Baseline Characteristics Smoked or vaped marijuana*	N=140	N=246	N=386	P-value
	67(47.9%)	139(56.5%)	206(53.4%)	.10
Smoked/snorted/inhaled heroin*	32(22.9%)	73(29.7%)	105(27.2%)	.15
Smoked/snorted/inhaled/vaped meth*	86(61.4%)	150(61.0%)	236(61.1%)	.93
Smoked/snorted/inhaled crack/cocaine*	15(10.7%)	22(8.9%)	37(9.6%)	.57
Injected heroin*	123(87.9%)	222(90.2%)	345(89.4%)	.46
Injected fentanyl*	27(19.3%)	50(20.3%)	77(19.9%)	.81
Median age at first injection	20.0(17.0,27.0)	19.0(17.0,25.0)	20.0(17.0,26.0)	.36
#Times injected drugs per day	2.5(0.3, 4.0)	2.5(0.7, 4.0)	2.5(0.3, 4.0)	.14
Visited shooting galleries*	12(8.6%)	19(7.7%)	31(8.0%)	.77
Used hit doctor*	25(17.9%)	46(18.8%)	71(18.4%)	.82
Crossed border to inject drugs*	60(42.9%)	97(39.4%)	157(40.7%)	.51
Co-Morbidities				
HIV-antibody positive	15(10.7%)	17(6.9%)	32(8.3%)	.25
HCV-antibody positive	47(33.6%)	86(35.1%)	133(34.5%)	.82
Diabetes ^Y	5(4.5%)	10(4.7%)	15(4.6%)	.92
Asthma ^Y	8(7.1%)	22(10.3%)	30(9.2%)	.35
Hypertension ^Y	13(11.6%)	25(11.7%)	38(11.7%)	.97
Preventive Measures				
Practiced social distancing ^Y	52(46.4%)	99(46.5%)	151(46.5%)	1.0
Wore face mask ^Y	85(75.9%)	154(72.3%)	239(73.5%)	.51
Increased handwashing/sanitizer ^Y	24(21.4%)	50(23.5%)	74(22.8%)	.78
Stocked up on drugs ^Y	18(16.1%)	35(16.5%)	53(16.4%)	1.0
Stocked up on harm reduction supplies ^Y	24(21.4%)	38(17.9%)	62(19.1%)	.45
Stopped smoking (current smokers) ^Y	6(6.3%)	4(2.1%)	10(3.5%)	.09
Avoided sharing drug paraphernalia ^Y	11(9.8%)	18(8.5%)	29(9.0%)	.69
Engaged in ≥1 protective behavior ^Y	101(90.2%)	190(89.2%)	291(89.5%)	.78
Had a prior COVID-19 test ^Y	42(37.5%)	63(29.6%)	105(32.3%)	.17

Table 2: Factors associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico

125

Baseline Characteristics	Univariate RR (95% CI)	
Sociodomographico	, ,	
Sociodemographics Male	1.01 (0.75,1.37)	
Age¥ [₽]	1.02 (1.00,1.03)	
Hispanic/Latinx/Mexican ^p	1.53 (1.08,2.15)	
Speaks English	0.85 (0.64,1.13)	
Born in the US	0.80 (0.61,1.04)	

Table 2 (continued): Factors associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico

	Univariate RR	
Baseline Characteristics	(95% CI)	
Sociodemographics (con't)		
Highest year of school completed¥	1.00 (0.96,1.04)	
Married or common law	0.92 (0.65,1.30)	
Average monthly income <500 USD	1.02 (0.78,1.33)	
Primary residence in San Diego	0.97 (0.74,1.28)	
Years lived in Study Location¥	1.01 (1.00,1.01)	
·	,	
Potential Exposures		
Homeless*	0.86 (0.65,1.14)	
Incarcerated*P	1.43 (0.99,2.09)	
Median # of people in household*¥	1.00 (1.00,1.00)	
Low/very low food security	0.93 (0.65,1.34)	
Engaged in sex work* ^p	1.53 (1.12,2.09)	
Client of sex worker*	1.24 (0.73,2.11)	
Exposed to someone with COVID-19	0.97 (0.49,1.89)	
Impact of Pandemic		
Housing situation worse	1.25 (0.94,1.65)	
Income worse	1.27 (0.94,1.71)	
	, ,	
Substance Use		
Smokes cigarettes	0.73 (0.52,1.01)	
Smoked or vaped marijuana*	0.80 (0.62,1.04)	
Smoked/snorted/inhaled heroin*	0.79 (0.57,1.10)	
Smoked/snorted/inhaled/vaped meth*	1.01 (0.77,1.33)	
Smoked/snorted/inhaled crack/cocaine*	1.13 (0.75,1.71)	
Injected heroin*	0.86 (0.58,1.27)	
Injected fentanyl*	0.96 (0.68,1.34)	
Median age at first injection¥	1.01 (0.99,1.02)	
#Times injected drugs per day¥	0.94 (0.87,1.02)	
Visited shooting galleries*	1.07 (0.67,1.71)	
Used hit doctor*	0.96 (0.68,1.36)	
Crossed border to inject drugs*	1.09 (0.84,1.43)	
Co-Morbidities		
HIV-antibody positive	1.33 (0.89,1.97)	
HCV-antibody positive	0.96 (0.72,1.27)	
Diabetes ^Y	0.97 (0.46,2.01)	
Asthma ^Y	0.76 (0.41,1.40)	
Hypertension ^Y	0.99 (0.62,1.58)	
	• • •	
Preventive Measures		
Practiced social distancing ^Y	1.00 (0.74,1.35)	
Wore face mask ^Y	1.13 (0.79,1.62)	

Table 2 (continued): Factors associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico

Baseline Characteristics	Univariate RR (95% CI)
Preventive Measures (con't)	
Increased handwashing/sanitizerY	0.93 (0.64,1.34)
Stocked up on drugs ^Y	0.98 (0.65,1.47)
Stocked up on harm reduction supplies ^Y	1.15 (0.81,1.65)
Stopped smoking (among current smokers) YP	1.86 (1.09,3.17)
Avoided sharing drug paraphernalia ^Y	1.11 (0.68,1.81)
Engaged in ≥1 protective behavior [∨]	1.07 (0.64,1.79)
Had a prior COVID-19 test ^{Yp}	1.26 (0.93,1.70)

^{*}past 6 months; Y Missing values: n=66 ¥ Per year increase; PP-value<0.10

In a multivariate model that controlled for sex (Table 3), each year in age was associated with a 2% increase in SARS-CoV-2 seropositivity (Adjusted relative risk (AdjRR): 1.02; 95% CI: 1.01-1.03). Identifying as Hispanic/Latinx/Mexican was also independently associated with SARS-CoV-2 seropositivity (AdjRR: 1.53; 95% CI: 1.09-2.15), as was engaging in sex work in the past six months (adjRR: 1.63; 95% CI: 1.18-2.27). Being incarcerated in the last six months remained marginally significant (AdjRR: 1.49; 95% CI: 0.97-2.27). When country of residence was forced into the model, all significant associations held except ethnicity. Excluding nine participants who reported having received at least one COVID-19 vaccine did not appreciably change parameter estimates.

Table 3: Factors Independently associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico

Baseline Characteristics	Adjusted RR** (95% CI)	
Male	1.02 (0.76, 1.37)	
Age [¥]	1.02 (0.76, 1.37)	
Hispanic/Latinx/Mexican	1.53 (1.09, 2.15)	
Engaged in sex work*	1.63 (1.18, 2.27)	
Incarcerated*	1.49 (0.97, 2.27)	

^{*}past 6 months; **variables in the multivariable model were adjusted for all the variables in the model;

Although 89.5% reported engaging in ≥1 protective behavior [e.g., face masks (73.5%)], only 46.5% reported social distancing, 22.8% increased handwashing/hand sanitizers, and 9.0% reported avoiding sharing drug paraphernalia in the prior six months (Table 1). None of these behaviors were significantly

[¥] Per year increase

associated with SARS-CoV-2 serostatus. Those testing SARS-CoV-2 seropositive were more likely to report having stopped smoking in the last six months and to have had a COVID-19 test.

Compared to non-sex workers, sex workers were just as less likely report protective behaviors but were significantly more likely to report being exposed to someone with COVID-19 (20% vs. 3.8%, p=0.001) or to have low/very low food security (94.3% vs. 77.9% p=0.02).

Discussion

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

In this community-based study of people who inject drugs in the San Diego-Tijuana border region, over one third had detectable SARS-CoV-2 antibodies, which exceeds estimates from the general population in either city. Modeling of the SARS-CoV-2 epidemic in San Diego County suggests that prevalence was below 5% through July, 2020 then increased to approximately 20% by January, 2021 (California Department of Public Health, unpublished data). In a household study conducted in Tijuana in February 2021, SARS-CoV-2 seroprevalence was 21% [11]. Reports in the literature of SARS-CoV-2 prevalence among people who inject drugs are sparse. In a study of needle exchange clients in Stockholm, Sweden, SARS-CoV-2 prevalence was 5.4% [12], whereas in a survey of people who inject drugs in England, Wales and Northern Ireland, 11% reported that they had tested positive for COVID-19 [13]. U.S. estimates among people who are homeless or living in shelters range from 2%-14% [14-16]. In our study, SARS-CoV-2 seroprevalence did not differ by country of residence, perhaps reflecting close social ties between San Diego and Tijuana communities despite the closure of the U.S.-Mexico border. In a phylogenetic analysis of SARS-CoV-2 sequences from the U.S. and Mexico, those obtained from the Mexican state of Baja California were more closely related to San Diego than to Mexico City.[17] Although one half of the San Diego residents in our study had crossed the border and injected drugs in Tijuana in the last six months, we found no evidence that cross-border mobility was associated with SARS-CoV-2 seropositivity. Consistent with other studies, subjects who were older [6] and who identified as Hispanic, Latinx, or Mexican [2] were significantly more likely to test SARS-CoV-2 seropositive. This demonstrates that even

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

among the lowest socioeconomic strata in the US and Mexico, ethnic disparities in SARS-CoV-2 seroprevalence persist. We did not observe substance use behaviors, such as smoking, vaping, or use of specific drugs such as opiates or stimulants to be associated with an elevated risk of SARS-CoV-2 infection, as others have hypothesized [4,6]. Instead, we observed that circumstances in the risk environment, notably sex work and incarceration, were associated with significantly higher SARS-CoV-2 seroprevalence. To our knowledge, ours is the first study to show that sex work is independently associated with higher SARS-CoV-2 prevalence after controlling for potential confounders such as sex, age, and ethnicity. In an unpublished study in Denmark, SARS-CoV-2 seroprevalence was higher among sex workers (12.2%) than people experiencing homelessness (6.8%) or the general population (2.9%) [18], but the independent effects of these and other factors were not assessed. Although the majority of our sample reported that COVID-19 had greatly affected their income and housing, sex workers may have faced additional hardships following the closure of the U.S.-Mexico border because of their reliance on sex tourism, and since social distancing is not possible during sexual transactions. Compared to the rest of the sample, significantly higher proportions of sex workers reported low or very low food insecurity, and they were more likely to report having been exposed to someone with COVID-19 than others. This suggests that sex workers may have engaged in higher risk behaviors to support themselves, placing them at greater risk of SARS-CoV-2 infection. In a study of female sex workers in Kenya, sexual transactions declined during the pandemic [19] and those most reliant on sex work reported greater food insecurity, which is consistent with our findings. Among female sex workers in Nigeria, those with knowledge about COVID-19 were significantly more likely to wear face masks, but less than half did so [20]. Despite concerns about sex workers' vulnerability to COVID-19, few countries provide them aid [19,21]. In Thailand, the Netherlands and Japan, sex workers were included in COVID-19 government-sponsored support programs [21], but they are excluded in countries where sex work is criminalized, such as the U.S. Although sex work is guasi-legal in Tijuana's red light district, those using drugs are less likely to obtain sex work permits and instead work outside of commercial establishments that could offer

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

protections [22]. In an earlier study, we found that female sex workers in Tijuana who inject drugs were more vulnerable to offers of unprotected sex in exchange for more money or drugs compared to those that did not inject [23]. Our finding that recent incarceration was independently associated with SARS-CoV-2 seropositivity could reflect institutional exposures. Over-crowding was implicated in COVID-19 outbreaks in California correctional institutions [24], including those in the U.S.-Mexico border region. Mitigation included early release, halting intakes, and eliminating bail, but a recent analysis suggests that considerable potential for SARS-CoV-2 exposures persist, at least in the California prison system [24]. Similar measures have not been undertaken in Baja California. Our study also found that over half of those testing SARS-CoV-2 seropositive had not been tested prior to study enrolment. These findings underscore the need to improve community outreach to provide testing, vaccines, and treatment, for example using mobile syringe exchange programs. **Limitations** Our ability to detect some associations was limited due to statistical power. Ours was a non-random sample and the cross-sectional study design precludes drawing causal inferences. Participants experiencing symptoms may have changed behaviors, such as stopped smoking or sought COVID-19 testing. Of note, none of the self-collected swabs tested positive for SARS-CoV-2 RNA. The sensitivity of the pooling approach could have been impacted by: 1) the viral load of any particular infected individual: 2) the consistency with which swabs were obtained; 3) storage, shipping, and transport conditions; or 4) of diluting out (via pooling) any viral SARS-CoV-2 RNA collected below the limit of detection. In this study, we limited our pools to ≤10 swabs, and previously validated our approach with up to 30 samples per pool where the limit of detection was estimated at 2.4 copies/µL [25]. Therefore, it is unlikely that we experienced loss of sensitivity due to pooling. Since SARS-CoV-2 antibodies may wane over time especially among patients who are asymptomatic or mildly symptomatic [26-27], infections that occurred earlier in the epidemic may have gone undetected.

However, the majority of participants testing SARS-CoV-2 seropositive had detectable IgM antibody titers, which is suggestive of recent infection [28]. Some misclassification could have occurred among those testing indeterminate who were recently infected, but these were few in number and would have tended to underestimate SARS-CoV-2 prevalence, dampening any observed associations.

Since COVID-19 vaccines did not become available to adults 18-65 years of age in San Diego County until May 15, 2021 and were not available to most adults in Tijuana until after the study period ended, we were unable to examine the impact of vaccination on SARS-CoV-2 infection. Nevertheless, among the 75 San Diego residents in our sample who were interviewed after May 15, only 9 (9.3%) reported having received at least one COVID-19 vaccine dose. In comparison, the proportion of adults aged ≥18 years who had received at least one COVID-19 vaccine dose in San Diego County through June 24, 2021 exceeded 50% [29].

Conclusions

We found that most people who inject drugs in the San Diego-Tijuana border region engaged in preventive measures to avoid SARS-CoV-2, but since over one-third had evidence of infection, a binational policy response is warranted beyond the closure of the U.S.-Mexico border. The proportion of participants who had previously been tested for SARS-CoV-2 or had received COVID-19 vaccine was very low. Efforts are needed to mitigate risks and provide COVID-19 vaccines to older and Hispanic people who inject drugs, especially those with less agency to protect themselves, such as those who are sex workers or incarcerated.

Acknowledgements

The authors gratefully acknowledge the La Frontera study team and participants in San Diego and Tijuana, staff at Genalyte and Fluxergy for assistance interpreting laboratory results, laboratory staff at the Center for AIDS Research, Dr Pamina Gorbach for assistance with survey measures, Dr. Davey Smith for helpful suggestions on the study design and Sharon Park for assistance with manuscript preparation.

References

245

268269

- Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. JAMA 2020;
 323(24): 2466-7.
- Macias Gil R, Marcelin JR, Zuniga-Blanco B, Marquez C, Mathew T, Piggott DA. COVID-19 Pandemic:
 Disparate Health Impact on the Hispanic/Latinx Population in the United States. J Infect Dis 2020;
 222(10): 1592-5.
- Reitsma MB, Claypool AL, Vargo J, Shete PB, McCorvie R, Wheeler WH, et al. Racial/Ethnic
 Disparities In COVID-19 Exposure Risk, Testing, And Cases At The Subcounty Level In California.
 Health Aff (Millwood) 2021; 40(6): 870-8.
- 4. Volkow ND. Collision of the COVID-19 and Addiction Epidemics. Ann Intern Med 2020; 173(1): 61-2.
- Genberg BL, Astemborski J, Piggott DA, Woodson-Adu T, Kirk GD, Mehta SH. The health and social
 consequences during the initial period of the COVID-19 pandemic among current and former people
 who inject drugs: A rapid phone survey in Baltimore, Maryland. Drug Alcohol Depend 2021; 221:
 108584.
- Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use
 disorders: analyses from electronic health records in the United States. Mol Psychiatry 2021; 26(1):
 30-9.
- Zolopa C, Hoj S, Bruneau J, Meeson JS, Minoyan N, Raynault MF, et al. A rapid review of the impacts of "Big Events" on risks, harms, and service delivery among people who use drugs: Implications for responding to COVID-19. Int J Drug Policy 2021; 92: 103127.
- U.S. Department of Agriculture (USDA) Economic Research Service. Food Security in the U.S. Measurement. 2020. https://www.ers.usda.gov/topics/food-nutrition-assistance/food-security-in the-us/measurement/#measurement (accessed June 29 2021).
 - 9. Food and Drug Administration (FDA). Maverick™ SARS-CoV-2 Multi-Antigen Serology Panel v2 01030ART-01. https://www.fda.gov/media/142915/download (accessed June 16 2021).
- 10. Ikegami S, Benirschke RC, Fakhrai-Rad H, Motamedi MH, Hockett R, David S, et al. Target specific serologic analysis of COVID-19 convalescent plasma. PLoS One 2021; 16(4): e0249938.
- 272 11. Consulado General de México en San Diego. Presentation of the results of the "Survey on Prevalence
 273 of Covid-19 in Baja California". 2021.
- https://consulmex.sre.gob.mx/sandiego/index.php/comunicados-2020/782-survey-on-prevalenceof-covid-19-in-baja-california (accessed July 15 2021).
- 12. Lindqvist K, Wallmofeldt C, Holmen E, Hammarberg A, Kaberg M. Health literacy and changes in
 pattern of drug use among participants at the Stockholm Needle Exchange Program during the
 COVID-19 pandemic. Harm Reduct J 2021; 18(1): 52.
- 279 13. Croxford S, Emanuel E, Ibitoye A, Njoroge J, Edmundson C, Bardsley M, et al. Preliminary indications 280 of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the 281 impact on access to health and harm reduction services. Public Health 2021; 192: 8-11.
- 14. Rogers JH, Link AC, McCulloch D, Brandstetter E, Newman KL, Jackson ML, et al. Characteristics of
 COVID-19 in Homeless Shelters: A Community-Based Surveillance Study. Ann Intern Med 2021;
 174(1): 42-9.
- Yoon JC, Montgomery MP, Buff AM, Boyd AT, Jamison C, Hernandez A, et al. COVID-19 Prevalence
 among People Experiencing Homelessness and Homelessness Service Staff during Early Community
 Transmission in Atlanta, Georgia, April-May 2020. Clin Infect Dis, 2020.
- 288 https://www.ncbi.nlm.nih.gov/pubmed/32898272 (accessed Sep 8).
- 16. Mosites E, Parker EM, Clarke KEN, Gaeta JM, Baggett TP, Imbert E, et al. Assessment of SARS-CoV-2
 Infection Prevalence in Homeless Shelters Four U.S. Cities, March 27-April 15, 2020. MMWR Morb
 Mortal Wkly Rep 2020; 69(17): 521-2.

- 17. San Diego Epidemiology and Research for COVID Health (SEARCH). SARS-CoV-2 Genomics. 2021.
 https://searchcovid.info/genomics/ (accessed June 29 2021).
- 18. Röthlin Eriksen AR, Fogh K, Hasselbalch RB, Bundgaard H, Nielsen S, Jørgensen C, et al. SARS-CoV-2
 antibody prevalence among homeless people, sex workers and shelter workers in Denmark: a
 nationwide cross-sectional study. medRxiv 2021: 2021.05.07.21256388.
- 19. Kavanagh NM, Marcus N, Bosire R, Otieno B, Bair EF, Agot K et al. Health and Economic Outcomes
 Associated With COVID-19 in Women at High Risk of HIV Infection in Rural Kenya. JAMA Network
 Open 2021; 4(6): e2113787-e.
 - 20. Avwioro G, Egwunyenga A, Adjekuko C, Mgbere O, Odibo E, Iyiola S, et al. Commercial Sex Work During Novel Coronavirus (SARS-CoV-2) Era in the Niger Delta Region: Relationships Between Knowledge, Preventive Practice, and Transmission Potential. Int J Womens Health 2021; 13: 509-23.
- 21. Platt L, Elmes J, Stevenson L, Holt V, Rolles S, Stuart R. Sex workers must not be forgotten in the COVID-19 response. Lancet 2020; 396(10243): 9-11.

301

302

327

- 305 22. Sirotin N, Strathdee SA, Lozada R, Nguyen L, Gallardo M, Vera A, et al. A comparison of registered and unregistered female sex workers in Tijuana, Mexico. Public Health Rep 2010; 125 Suppl 4: 101-9.
- 307 23. Strathdee SA, Lozada R, Martinez G, Vera A, Rusch M, Nguyen L, et al. Social and structural factors 308 associated with HIV infection among female sex workers who inject drugs in the Mexico-US border 309 region. PLoS One 2011; 6(4): e19048.
- 24. Chin ET, Ryckman T, Prince L, Leidner D, Alarid-Escudero F, Andrews JR et al. Covid-19 in the California State Prison System: An Observational Study of Decarceration, Ongoing Risks, and Risk Factors. medRxiv, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33758868 (accessed Mar 8).
- Rawlings SA, Ignacio C, Porrachia M, Du P, Smith DM, Chaillon A. No Evidence of SARS-CoV-2 Seminal
 Shedding Despite SARS-CoV-2 Persistence in the Upper Respiratory Tract. Open Forum Infect Dis
 2020; 7(8): ofaa325.
- 26. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med 2020; 383(11): 1085-7.
- 27. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26(8): 1200-4.
- 28. Chen Y, Li P, Ding Y, Liu M, Liu L, Yi B, et al. Epidemiological feature, viral shedding, and antibody seroconversion among asymptomatic SARS-CoV-2 carriers and symptomatic/presymptomatic COVID-19 patients. J Infect Public Health 2021; 14(7): 845-51.
- 29. County of San Diego. COVID-19 Vaccinations Report San Diego County Residents with COVID19
 Vaccinations by Age Group. 2021.
- https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/Epidemiology/COVID-19%20Vaccinations%20by%20Age%20Group.pdf (accessed June 29 2021).